Moreover, in the CANTOS trial, administration of canakinumab (a monoclonal antibody targeting IL-1β) prevented the recurrence of ischemic events, reduced heart failure-related hospitalizations and mortality in patients with prior AMI (Buckley and Abbate, 2018). This evidence concerns the gene IL1B and heart failure.